The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients
- 28 November 2006
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 82 (5), 403-404
- https://doi.org/10.1002/ajh.20838
Abstract
Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia. We used bortezomib in ten refractory or relapsed patients (seven of multiple myeloma, two of lymphoma and one of acute myeloblastic leukemia). Six out of ten (60%) patients developed varicella herpes zoster after the complete of one cycle of bortezomib. The incidence of varicella herpes zoster was higher than reported in the literature. It may be due to immunosuppression caused by the combination of high‐dose dexamethasone or other drugs. We considered that prophylactic antiviral medication could be used in predisposed patients to reduce the incidence of varicella herpes zoster. Am. J. Hematol., 2007.Keywords
This publication has 8 references indexed in Scilit:
- Use of bortezomib in B-cell non-Hodgkin’s lymphomaExpert Review of Anticancer Therapy, 2006
- Inhibition of the NF-κB Pathway by Varicella-Zoster Virus In Vitro and in Human Epidermal Cells In VivoJournal of Virology, 2006
- Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.Blood, 2005
- Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).Blood, 2005
- Bortezomib interactions with chemotherapy agents in acute leukemia in vitroCancer Chemotherapy and Pharmacology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory DiseasesNew England Journal of Medicine, 1997